Patients with cervical cancer stage II to III without obstructive uropathy underwent CCRT Cervical cancer CCRT Oral post hydration Intravenous post hydration
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Cervical cancer patients with proven cell type of squamous cell carcinoma or adenocarcinoma stage II or III (FIGO) without obstructive uropathy underwent concurrent-chemoradiation therapy 2. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
Exclusion criteria
Exclusion criteria: 1.Serum creatinine level prior treatment > 1.2 mg/dl 2.Unstable vital signs 3.Known medical issues: Cardiac diseases, Liver diseases, Renal diseases 4.History of allergy to cisplatin 5.Pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean difference in serum creatinine pre and post treatment with cisplatin during CCRT oral vs IV - Serum creatinine level pre and post each course of cisplatin during CCRT | — |
Secondary
| Measure | Time frame |
|---|---|
| None None None | — |
Contacts
Prince of Songkhla University